Vanda Pharmaceuticals (VNDA) Cash & Current Investments (2009 - 2026)

Vanda Pharmaceuticals' Cash & Current Investments history runs 18 years deep, the most recent figure standing at $202.3 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 40.66% year-over-year to $202.3 million; the TTM figure through Mar 2026 stood at $202.3 million (down 40.66% YoY), while the FY2025 annual figure was $263.8 million, down 29.57% from the prior year.
• Cash & Current Investments came in at $202.3 million for Q1 2026 at Vanda Pharmaceuticals, down from $263.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $501.5 million in Q1 2023 to a low of $202.3 million in Q1 2026.
• A 5-year average of $389.7 million and a median of $388.3 million in 2023 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments gained 15.24% in 2023 and slumped 40.66% in 2026, its largest moves.
• Vanda Pharmaceuticals' Cash & Current Investments stood at $466.9 million in 2022, then retreated by 16.83% to $388.3 million in 2023, then decreased by 3.51% to $374.6 million in 2024, then slipped by 29.57% to $263.8 million in 2025, then slipped by 23.32% to $202.3 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $202.3 million, $263.8 million, and $293.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison